Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 100 of 406 for:    PYY

Gastric Activity and Gastrointestinal Peptides in Patients With Functional Dyspepsia (DYSMOT-RIII)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02113527
Recruitment Status : Completed
First Posted : April 14, 2014
Last Update Posted : September 2, 2015
Sponsor:
Information provided by (Responsible Party):
Francesco Russo, Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

Brief Summary:

Rome III criteria defined functional dyspepsia (FD) as the presence of symptoms from the gastroduodenal region in the absence of any organic, systemic or metabolic disease that is likely to explain the symptoms. FD can be further subdivided into two diagnostic categories: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS).

Disorders of gastric electric activity and abnormal gastric emptying are probably actively involved in the FD onset. Different noninvasive procedures may be applied in order to evaluate the gastric motor functions such as 13C breath testing and cutaneous electrogastrography. Besides, different gastrointestinal peptides (i.e. CCK, peptide YY, Neurotensin, Somatostatin, Leptin, Ghrelin, Motilin, Gastrin, Pepsinogen I and II) are involved in the control of gastroduodenal motility.

Aims of the present study are: 1) to evaluate the GI peptide circulating concentrations, the gastric electrical activity and gastric emptying time by applying noninvasive procedures in patients suffering from functional dyspepsia and 2) to test whether a significant difference exists between the two diagnostic categories of meal-induced dyspeptic symptoms


Condition or disease
Dyspepsia

Detailed Description:

Functional dyspepsia is one of the most relevant functional gastrointestinal disorders (FGIDs) among general population. Rome III criteria defined functional dyspepsia as the presence of symptoms from the gastroduodenal region (early satiation, postprandial fullness, epigastric pain or burning) in the absence of any organic, systemic or metabolic disease that is likely to explain the symptoms. Etiological causes are still unclear, and the pathophysiological mechanisms still largely unknown. Besides, Helicobacter pylori infection is often present in these patients and contributes to complicate the clinical presentation. One of the main problem in the management of these patients is the lack of reliable biohumoral markers. Thus, functional disorders are usually diagnosed on the bases of symptomatic patterns. The Rome consensus has proposed to further subdivide FD into two diagnostic categories of meal-induced dyspeptic symptoms: postprandial distress syndrome (PDS), characterized by postprandial fullness and early satiation, and epigastric pain syndrome (EPS), characterized by epigastric pain and burning.

Central processing of visceral stimuli, and its role in the pathogenesis of functional dyspepsia, as well as low-grade inflammation in the duodenum are important emerging topics in pathophysiology research. In this framework, disorders of gastric electric activity and abnormal gastric emptying are probably actively involved in the onset of symptomatology. Different noninvasive procedures may be applied in order to evaluate the gastric motor functions. Among them, gastric emptying time evaluation by 13C breath testing and cutaneous electrogastrography have raised attention for their reliability and potentiality. Another important pathophysiological concern of FD is represented by the possible alterations in circulating concentrations of different gastrointestinal peptides at various degree involved in the control of gastroduodenal motility [namely Cholecystokinin (CCK), peptide YY, Neurotensin, Somatostatin, Leptin, Ghrelin, Motilin, Gastrin, Pepsinogen I and II]. In previous studies significant lower levels of motilin was found in dyspeptic patients with altered antroduodenal motility was found. CCK mediates satiety by acting on the CCK receptors distributed widely throughout the central nervous system as well as effects on the vagus nerve. Other experimental data suggest that somatostatin and neurotensin may affect muscle contractility and delay the intestinal transit.

On these bases aims of the study will be: 1) to evaluate the GI peptide circulating concentrations, the gastric electrical activity and gastric emptying time by applying noninvasive procedures in patients suffering from functional dyspepsia and 2) to test whether a significant difference exists between the two diagnostic categories of meal-induced dyspeptic symptoms


Layout table for study information
Study Type : Observational
Actual Enrollment : 75 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Evaluation of Gastric Emptying Time, Gastric Electrical Activity and Gastrointestinal Peptides to Identify Dyspeptic Patients With Epigastric Pain Syndrome From Those With Postprandial Distress Syndrome According to the Rome III Proposed Subdivision of Functional Dyspepsia
Study Start Date : April 2014
Actual Primary Completion Date : November 2014
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Indigestion

Group/Cohort
Epigastric pain syndrome (EPS)
Patients suffering from functional dyspepsia characterized by epigastric pain syndrome according to Rome III criteria
Postprandial distress syndrome (PDS)
Patients suffering from functional dyspepsia characterized by postprandial distress syndrome according to Rome III criteria
Healthy subjects
Healthy subjects as control group



Primary Outcome Measures :
  1. Fasting plasma concentration of GI peptides, gastric emptying time and dyspepsia subtype. [ Time Frame: Duration of 4-hour study visit ]

    Exploration of relationships between GI peptide concentrations (CCK, peptide YY, Neurotensin, Somatostatin, Leptin, Ghrelin, Motilin, Gastrin, Pepsinogen I and II), solid gastric emptying, and dyspepsia subtype.

    Blood samples will be compared pre/post test meal for FD cohorts (EPS/PDS) and controls: 0 time/baseline and 16 times/post meal.

    Associations of plasma GI peptides pre and postprandial levels & gastric emptying will be studied.

    Amount of 13CO2 will be determined for each time point (1 pre/ 16 post meal) using equation nested in software package with IRMS.

    The concentration of 13CO2 and 12CO2 in the exhaled breath samples will be measured by mass spectrometry.



Secondary Outcome Measures :
  1. Gastric electrical activity and GI peptides according functional dyspepsia subtype [ Time Frame: Duration of 4-hour study visit ]

    Correlations between plasma GI peptide concentrations and gastric electrical activity to be measured during gastric emptying time evaluation.

    Gastric electrical activity will be measured by cutaneous electrogastrography.



Biospecimen Retention:   Samples With DNA
breath specimen, whole blood, serum, white cells.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients will be recruited in this observational study from the out-patients of the National Institute of Digestive Diseases, I.R.C.C.S. Saverio de Bellis, Castellana Grotte, Bari, Italy.
Criteria

Inclusion Criteria:

  • Patients suffering from dyspeptic symptoms according to Rome III;
  • Helicobacter pylori negative subjects;
  • age 19-70 yr.;
  • willingness to complete the study;
  • not recent administration (in the 2 months before the examination) of anti-inflammatory drugs (NSAIDs), antibiotics, bismuth, antacids, H2-receptor antagonists, proton pump inhibitor, sucralfate or misoprostol;
  • at least one endoscopic/radiological GI evaluation in the last 5 yrs.

Exclusion Criteria:

  • previous history of gastric tumors or gastric surgery
  • lactose intolerance;
  • celiac disease, wheat sensitivity;
  • alarm symptoms (GI bleeding, weight loose etc.);
  • psychiatric diseases;
  • familial history of peptic ulcer;
  • gastric cancer or IBD;
  • abnormal thyroid function;
  • other exclusion criteria (namely, pregnancy, breast-feeding, and drug allergies).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02113527


Locations
Layout table for location information
Italy
National Institute of Digestive Diseases IRCCS "Saverio de Bellis"
Castellana Grotte, Bari, Italy, 70013
Sponsors and Collaborators
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Investigators
Layout table for investigator information
Principal Investigator: Francesco Russo, MD IRCCS "S. de Bellis"

Publications:
Layout table for additonal information
Responsible Party: Francesco Russo, Senior researcher, Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
ClinicalTrials.gov Identifier: NCT02113527     History of Changes
Other Study ID Numbers: RC192014
First Posted: April 14, 2014    Key Record Dates
Last Update Posted: September 2, 2015
Last Verified: September 2015
Keywords provided by Francesco Russo, Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis:
Electrogastrography
Functional dyspepsia
Gastric emptying
Gastrointestinal peptides
Rome III criteria
Additional relevant MeSH terms:
Layout table for MeSH terms
Dyspepsia
Signs and Symptoms, Digestive
Signs and Symptoms